Agar-derived oligosaccharides inhibit Staphylococcus growth
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid spread of antibiotic-resistant Staphylococcus bacteria, particularly Staphylococcus aureus, poses significant challenges due to its ability to form biofilms, evade immune functions, and develop resistance to conventional antibiotics, leading to difficult-to-treat infections and high mortality rates.
Innovation Solution
The use of agar-derived oligosaccharides, specifically agarooligosaccharides, agarobiose, and 3,6-anhydro-L-galactose (AHG), which are derived from agar and form mixtures such as agarobiose, agarotetraose, agarohexaose, and agarooctaose, to inhibit or kill Staphylococcus bacteria, offering a potential alternative treatment in medical, cosmetic, food, and industrial applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat Staphylococcus infections, then initial treatment effectiveness is improved, but bacterial resistance develops leading to treatment failure
Solution Approach 1:
The patent utilizes the unique molecular structure of agar-derived oligosaccharides, particularly the non-reducing sugar 3,6-anhydro-L-galactose (AHG), to create antibacterial compounds that exploit bacterial vulnerability without triggering resistance mechanisms. The specific galactose-based structure interferes with bacterial cell wall synthesis and membrane integrity, converting the natural bacterial metabolism into a weakness that these compounds can exploit.
Solution Approach 2:
The invention changes the chemical parameter space by using oligosaccharides with specific degree of polymerization (DP2-DP8) and particular structural features (3,6-anhydro-L-galactose units) that differ fundamentally from conventional antibiotics. This parameter change in molecular structure allows the compounds to interact with bacterial targets through different mechanisms, avoiding the resistance pathways that have developed against traditional antibiotic classes.
2Object-generated harmful factors
If synthetic peptides are used as alternative anti-staphylococcal substances, then antibiotic resistance is avoided, but safety and harmlessness to human body must be ensured
Solution Approach 1:
The patent employs oligosaccharides that are naturally derived from agar, a renewable marine resource, making them inherently biocompatible and safe for human use. These compounds are designed to exert their antibacterial effect and then be naturally metabolized or excreted, avoiding accumulation in the human body. The use of food-grade agar derivatives ensures safety while maintaining effectiveness against Staphylococcus.
3Reliability
If agar-derived oligosaccharides are used to inhibit Staphylococcus growth, then antibacterial effectiveness is improved, but the complexity of identifying specific active compounds increases
Solution Approach 1:
The patent systematically segments the complex agar oligosaccharide mixture into discrete molecular weight fractions with specific degree of polymerization (DP2, DP3, DP4, DP6, DP8). This segmentation allows identification of the most active fractions while simplifying the overall characterization process. The approach breaks down the complex natural product into manageable, characterizable units with defined structures and activities.
Solution Approach 2:
The patent uses 3,6-anhydro-L-galactose (AHG) as a key structural intermediary and marker compound to track and identify the active oligosaccharide fractions. AHG serves as a characteristic structural element that simplifies the identification process, as its presence and configuration can be detected and used to characterize the active compounds without requiring complete structural analysis of each oligosaccharide variant.
Data Source
AI summary
The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.